Concepedia

Ezequiel Neimark

EN

Statistics

Publications

23

Citations

3.2K

H-Index

16

Active since

2003

Affiliations

AbbVie (United States)(Current)

Icahn School of Medicine at Mount Sinai

University of Calgary

Imelda Hospital

AbbVie (Germany)

Ezequiel Neimark is an author at AbbVie (United States) specializing in inflammatory bowel disease, inflammatory bowel disease therapy, and crohn disease pharmacotherapy.

Publications per year

2003–2025

23

Publications

23

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt et al. · The Lancet · 2017 · 912 citations

, , +3

Guideline for the Evaluation of Cholestatic Jaundice in Infants

Rima Fawaz, Ulrich Baumann, Udeme D. Ekong et al. · Journal of Pediatric Gastroenterology and Nutrition · 2016 · 524 citations

, , +17

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 387 citations · Full text

, , +9

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 316 citations · Full text

, , +11

Bile acid-induced negative feedback regulation of the human ileal bile acid transporter

Ezequiel Neimark, Frank Chen, Xiaoping Li et al. · Hepatology · 2004 · 234 citations · Full text

, , +16

1–5 of 23